- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
TYK Medicines Inc (2410)
TYK Medicines Inc stock price live, this page displays HK 2410 stock exchange data. View the 2410 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the TYK Medicines Inc real time stock price chart below.
What Is the TYK Medicines Inc Stock Price Today?
The TYK Medicines Inc stock price today is 7.07.
What Is the Stock Symbol for TYK Medicines Inc?
The stock symbol for TYK Medicines Inc is "2410."
What Stock Exchange Does TYK Medicines Inc Trade On?
TYK Medicines Inc is listed and trades on the Hong Kong stock exchange.
Is TYK Medicines Inc a Good Stock to Buy?
Determining whether TYK Medicines Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2410 quote. (ISIN: CNE100006L34)
What Is the TYK Medicines Inc Stock Price Today?
The TYK Medicines Inc stock price today is 7.07.
What Is the Stock Symbol for TYK Medicines Inc?
The stock symbol for TYK Medicines Inc is "2410."
What Stock Exchange Does TYK Medicines Inc Trade On?
TYK Medicines Inc is listed and trades on the Hong Kong stock exchange.
Is TYK Medicines Inc a Good Stock to Buy?
Determining whether TYK Medicines Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2410 quote. (ISIN: CNE100006L34)
Hong Kong
Currency in HKD
7.07
-0.10(-1.39%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.93
7.33
52 wk Range
5.35
22.65
2410 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.937.33
52 wk Range
5.3522.65
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2410 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
24.10
Upside
+240.90%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock generally trades with high price volatility
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 24.10
(+240.90% Upside)
Earnings
Latest Release
Mar 30, 2026
EPS / Forecast
-0.50 / --
Revenue / Forecast
-- / --
Compare 2410 to Peers and Sector
Metrics to compare | 2410 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2410PeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.9x | −20.0x | −0.3x | |
PEG Ratio | −0.26 | 0.02 | 0.00 | |
Price/Book | 8.3x | 7.0x | 2.6x | |
Price / LTM Sales | - | 11.2x | 2.9x | |
Upside (Analyst Target) | 236.8% | 34.7% | 56.7% | |
Fair Value Upside | Unlock | 0.1% | 10.2% | Unlock |
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including breast cancer and prostate cancer; TY-2136b, an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor for the treatment of solid tumors; TY-2699a, a selective CDK7 inhibitor for the treatment of advanced/metastatic solid tumors; and TY-0540, a selective CDK2/4/6 inhibitor to treat advanced/metastatic solid tumors. In addition, it develops TY-1054, an oral yes associated protein-transcriptional enhanced associate domain inhibitor for cancer treatment; CDK4, preclinical-stage oral CDK4 inhibitor for cancer treatment; TY-3002, a small-molecule, orally administered glucagon like peptide-1 receptor agonist (GLP-1RA) intended for the treatment of type 2 diabetes mellitus (T2DM) and obesity; and EGFR/FAK (PROTAC) and PI3Ka to treat solid tumors; and GLP-1 for the treatment of T2DM and overweight or obesity. The company has a collaboration agreement with Qilu for development, manufacturing, and commercialization of TY-9591, a highly selective, irreversible EGFR-TKI self-developed by TYK Medicines to reduce the formation of toxic metabolites. The company was incorporated in 2017 and is headquartered in Huzhou, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the TYK Medicines (2410) Stock Price Today?
The TYK Medicines stock price today is 7.07 HKD.
What Stock Exchange Does TYK Medicines Trade On?
TYK Medicines is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for TYK Medicines?
The stock symbol for TYK Medicines is "2410."
What Is the TYK Medicines Market Cap?
As of today, TYK Medicines market cap is 2.76B HKD.
What Is TYK Medicines's Earnings Per Share (TTM)?
The TYK Medicines EPS (TTM) is -0.80.
From a Technical Analysis Perspective, Is 2410 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has TYK Medicines Stock Split?
TYK Medicines has split 0 times.
How Many Employees Does TYK Medicines Have?
TYK Medicines has 173 employees.
What is the current trading status of TYK Medicines (2410)?
As of Jul 30, 2026, TYK Medicines (2410) is trading at a price of 7.07 HKD, with a previous close of 7.17 HKD. The stock has fluctuated within a day range of 6.93 HKD to 7.33 HKD, while its 52-week range spans from 5.35 HKD to 22.65 HKD.
What Is TYK Medicines (2410) Price Target According to Analysts?
The average 12-month price target for TYK Medicines is 24.10 HKD, with a high estimate of 24.10173783 HKD and a low estimate of 24.10173783 HKD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +240.90% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.